## Novartis Patient Support<sup>™</sup>

1. Patient Information

# FABHALTA® (iptacopan) START FORM

\*=REQUIRED FIELDS

Please fill out all fields on this form to enroll in Novartis Patient Support.

First Name*	Last Name*		Email		
/	Sex for Clinical Use*:	Male Female		Mobile Home	
Date of Birth (MM/DD/YYYY)*			Phone Number**-	We'll keep you updated through non-marketing calls and texts	
Address (No PO Box)*			OK to Leave Voicen	nail: 🗌 Yes 🔲 No	
Address (NO PO Box)*			Due ferme all account		
City	State	ZIP	Preferred Language	e: English Spanish Other:	
I give permission to disclose my pe	rsonal health information to the	e following Caregive	er (optional):		
Caregiver Name		Relationship	to Patient		
Caregiver Phone Number—We'll kee		calls and texts.			
2. Patient Authorization and		onsents			
I have read and agree to the Patie	ent Authorization on page 3.			, ,	
Retient / Authorized Penro	contativo Signaturo*			/ / / Date (MM/DD/YYYY)*	
Patient/Authorized Repre				Date (MINI/DD/1111).	
CO-PAY PLUS <sup>§</sup>		ONGOING SUPPORT FR	OM NOVARTIS PATIENT SUP	PORT	
If you have private insurance, you may be eligible for the \$0 Co-Pay Plus Offer by checking the box below. You can also get concerning the box below.			ntinued one-on-one support from your dedicated Novartis Patient Support Team by checking the		
I have read and agree to the Co-Pay Plu	s Terms and Conditions on page 3.	texts made with an	eceive marketing calls and texts from and on behalf of Novartis and its affiliates, including calls and e with an autodialer or prerecorded voice, at the phone number(s) I provide. I understand that my not required and is not a condition of receiving any goods or services from Novartis.		
3. Insurance Information					
To prevent delays, please include	e copies (front and back) of t	he patient's presci	iption insurance ca	rd(s). Include primary, secondary, and	
prescription insurance, if separate		•	-	, , ,	
Check all that apply*:  Prima	ary Secondary Pres	cription	nt Is Uninsured		
4. Prescriber Information					
First Name*	_ast Name*	Practic	ce Name		
ddress Practic			e Phone Number		
		Office	Contact Name	Office Contact Phone	
City	State ZIP*	Office			
City S Prescriber NPI Number*	State ZIP*	Office	Fax*	Office Email	

Complete entire form and fax to Novartis Patient Support at 1-877-44FABHA (1-877-443-2242).

An incomplete Start Form may delay the start of treatment.

 $egin{array}{c} egin{array}{c} \egin{array}{c} \egin{array}$ 

### Novartis Patient Support

## FABHALTA® (iptacopan) START FORM

5. Vaccination Information	Patient Name* Date of Birth	Date of Birth (MM/DD/YYYY)*					
FABHALTA is available through a Risk Evalonline at www.FABHALTA-REMS.com.	luation and Mitigation Strategy (REMS) program. Add	ditional information is available by te	elephone at 1-866-201-3101 or				
	d sign the prescriber attestation*: hteria, including Streptococcus pneumoniae and Neisseri htiation of FABHALTA. Current ACIP recommendations a						
prescribed and will be continued until vac OR  HOLD SHIPMENT—CONTACT OFFIC	on requirements and my patient's vaccination history and ccinations have been completed. FABHALTA is authorized EE PRIOR TO DISPENSE	d to be dispensed as soon as possible.					
provided to my office as necessary.	on requirements and my patient's vaccination history, and	Trequest that the FABHALTA shipmer	nt be neid with additional follow-up				
more information.	ur patient's vaccination support needs. A dedicated		up with your patient and provide				
☐ My patient requires vaccination support <sup>†</sup>	only and no other services						
Please provide relevant vaccination and a	antibiotic prophylaxis information for your patient be	elow to support REMS requirement	ts for FABHALTA:				
► Antibiotic prophylaxis administered? ☐ Yes ☐ No If yes, start date:/							
➤ Vaccines administered? Document the app	propriate vaccine type, brand administered, and the admir	nistration date (using the MM/DD/YYY	Y format) of the most recent dose.				
	MenACWY  1st Dose Date:// 2nd Dose Date://  Menveo Menactra MenQuadfi Menveo Menactra MenQuadfi						
MenB 1st Dose Date: Bexsero			Dose Date:///				
Pneumococcal         1st Dose Date:        /         2nd Dose Date:        //							
6. Prescription Information							
Preferred Specialty Pharmacy: Onco	360 Biologics Other:						
Primary Diagnosis Code*: D59.5 Paroxysmal nocturnal hemoglobinuria Other:							
Has your patient previously taken any treatm	nents for their current condition in the past? $\ $ Yes $\ $	No If yes, please indicate:					
Pharmacy Prescription:							
Product Information	Dosage and Administration	Quantity (60 or 180 capsules)	Refills				
FABHALTA 200 mg capsule	200 mg orally twice daily	capsules	11 refills, orrefills				
the patient named on this form. I certify that a Patient Assistance Foundation, Inc., and its s for credit, or submitted for reimbursement in that Novartis and NPAF may revise, change, electronically, by facsimile, or by mail to the a authorized me under HIPAA and state law enrollment, Novartis may contact the pat	ssary and this information is accurate to the best of my known medication received from Novartis Pharmaceuticals Conservice providers ("NPAF"), will be used only for the patient in any form. I acknowledge that NPAF is exclusively for purply, or terminate their respective programs at any time. I author appropriate dispensing pharmacies. I have discussed the word to disclose their information to Novartis for the limite	Corporation, its affiliates and service pro named on this form and will not be offer loses of patient care and not for remune prize Novartis and NPAF to forward, as n Novartis Patient Support Program v	oviders ("Novartis") or the Novartis red for sale, trade, or barter, returned eration of any sort. I understand my agent, these prescriptions with my patient, who has				
Prescriber Signature (Dispense	as Writton) (Substitution Dormissible)	Procesiber Name (Print Nam	Data (MM/DD/VVVV)*				
Prescriber Signature (Dispense as Written) (Substitution Permissible) Prescriber Name (Print Name)* Date (MM/DD/YYYY)*  ATTN: Please follow your state's prescribing guidelines for electronic prescriptions (if applicable).							

 $egin{array}{c} egin{array}{c} \egin{array}{c} \egin{array}{c} \egin{array}{c} \egin{array}{c} \egin{array}{c} \egin{array}$ 

Complete entire form and fax to Novartis Patient Support at 1-877-44FABHA (1-877-443-2242).

An incomplete Start Form may delay the start of treatment.

**Questions? Call** 

1-833-99FABHA (1-833-993-2242)

Send Fax

Page 2 of 3

**1-877-44FABHA** (1-877-443-2242)

## 

## **Novartis Patient Support**

### **Patient Authorization**

l authorize my healthcare providers, pharmacies and health insurers, and their service providers ("Providers") to disclose information relating to my insurance benefits, medical condition, treatment, and prescription details ("Personal Information") to Novartis Pharmaceuticals Corporation, its affiliates and service providers ("Novartis") and the Novartis Patient Assistance Foundation, Inc., and its service providers ("NPAF") so they can provide the following support services (the "Services"):

- Help coordinate insurance coverage for, access to, and receipt of my medication.
- Communicate with me about possible financial assistance, including Novartis copay or NPAF programs, and, if I am enrolled, administer my participation in those programs.
- Communicate with me about my medication and treatment, including reminders, health and lifestyle tips, and product and other related information. Communications may be customized based on Personal Information obtained from my Providers.
- Conduct quality assurance and other internal business activities and ask for feedback related to the Services or my treatment.

In delivering the Services, Novartis and NPAF may share my Personal Information with each other, with my Providers, or with government agencies or other financial assistance programs that might help me pay for my medication. They may combine information collected from me with information collected from other sources and use that information to administer the Services. My pharmacies or other healthcare providers may receive payment from Novartis or NPAF for providing certain Services, such as medication or refill reminders, based on my enrollment or participation. Once I authorize disclosure of my Personal Information, it may no longer be protected by federal health privacy law and applicable state laws.

Lunderstand I do not have to sign this Authorization to get my medication or insurance coverage, that I have a right to a copy, and can cancel this Authorization at any time by calling 1-833-99FABHA (1-833-993-2242) or by writing to:

> **Novartis Patient Support Novartis Pharmaceuticals Corporation** One Health Plaza East Hanover, NJ 07936-1080

This Authorization will expire 5 years after I sign it, or earlier if required by state law, unless I cancel it sooner. If I cancel it, I may no longer qualify for Services from Novartis or NPAF, but it will not impact my Provider's treatment or my insurance benefits. I also understand that if a Provider is disclosing my Personal Information to Novartis or NPAF on an authorized, ongoing basis, my cancellation will be effective with respect to that Provider as soon as they receive notice of my cancellation. Cancellation will not affect prior uses or disclosures.

#### **Novartis Patient Support Terms and Conditions**

\*Vaccination Support: Limitations apply. Please contact Novartis Patient Support at 1-833-99FABHA (1-833-993-2242) for more information.

©Co-Pay Plus: Limitations apply. Patients with commercial insurance coverage for FABHALTA may receive up to \$20,000 in annual co-pay benefits for the cost of FABHALTA and up to \$1,000 for qualifying vaccination costs (excluding administrative fees). Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States, Puerto Rico and select territories. Void where prohibited by law, Additional restrictions may apply. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

Bridge Program: Limitations apply. Patients with commercial insurance, a valid prescription for FABHALTA, and a denial of insurance coverage based on a prior authorization requirement may receive a monthly dose for up to 12 months or until insurance coverage approval, whichever occurs first. Not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, VA, DoD or any other federal or state program, or where prohibited by law. A prior authorization and/or appeal of coverage denial must be submitted within 90 days to remain in the program. No purchase necessary. Program is not health insurance, nor is participation a quarantee of insurance coverage. Additional restrictions may apply, Novartis reserves the right to rescind, revoke or amend this Program without notice.

Novartis Patient Support may call and text you at the numbers provided for non-marketing purposes (e.g., to help you access and start on FABHALTA). Calls may be autodialed or prerecorded. Message and data rates may apply. You may change your communication preferences at any time by calling 1-833-99FABHA (1-833-993-2242).

Please see full Prescribing Information, including Boxed WARNING and Medication Guide.

Please see the Novartis Pharmaceuticals Corporation Privacy Policy at <a href="http://www.novartis.com/us-en/privacy">http://www.novartis.com/us-en/privacy</a>.

FABHALTA and FABHALTA logo are registered trademarks of Novartis AG.





4/24